HIGHLIGHTS FROM ASCO 2010

Tables and figures from selected presentations

2

MPR versus Tandem MEL200 + ASCT as Consolidation Therapy in NDMM

Rd(N = 402)

MPR(n = 202)

MEL200(n = 200)

P value(MPR vs. MEL200)

Efficacy

CR, %VGPR, %PR, %

63149

134236

163738

NSNSNS

PFS at 12 months, % — 91 91 NS

OS at 12 months, % — 97 98 NS

Grade 3/4 AEs

HematologicNeutropenia, %Thrombocytopenia, %

93

458

8687

< 0.001< 0.001

Non-hematologicInfectionsGastrointestinal

——

00

1523

< 0.001< 0.001

Adapted from Palumbo AP, et al. ASCO 2010. Abstract 8015 (oral presentation).

INDUCTION CONSOLIDATION

NS, not significant

3

Meta-analysis of MP vs. MPT

GIMEMA IFM I IFM II NMSG HOVON TMSG

Age, years > 65 65-74 > 75 > 65 > 65 > 55

N 331 321 229 354 333 114

Placebo No No Yes Yes No No

Melphalan 4 mg/m2 0.25 mg/kg 0.20 mg/kg 0.25 mg/kg 0.25 mg/kg 9 mg/m2

Prednisone 40 mg/m2

days 1-72 mg/kgdays 1-4

2 mg/kgdays 1-4

100 mgdays 1-4

1 mg/kgdays 1-5

60 mg/m2

days 1-4

No. of cycles 6 12 12 Until plateau ≥ 8 8

No. of weeks per cycle 4 6 6 6 4 6

Thalidomide 100 mg 200-400 100 200-400 200 100

Duration of thalidomide Until relapse 12 cycles 12 cycles Until relapse 4 weeks after

last cycle 8 cycles

Adapted from Waage A, et al. ASCO 2010. Abstract 8130 (poster presentation).

4

Carfilzomib in R/R MM

BTZ-treatedCohort 1 (n = 36)

BTZ-naïveCohort 1 (n = 59)

BTZ-naïveCohort 2 (n = 60)

Carfilzomib dose 20 mg/m2 20 mg/m2 20 mg/m2 cycle 127 mg/m2 cycle 2+

Evaluable for response 34 53 53

Overall response rate (≥PR) 21% 45% 55%

Median duration of response (≥MR) 8.5 months 8.3 months 11.5 months

Median time to progression 8.1 months 8.3 months 11.5 months

Adapted from Vij R, et al. ASCO 2010. Abstract 8000 (oral presentation).

5

New Combinations with Lenalidomide/dex in R/R MM Presented at ASCO 2010

CARFILZOMIB PANOBINOSTAT VORINOSTAT EVEROLIMUS ELOTUZUMAB

Author/Abstract No. Bensinger/8029 Mateos/8030 Richardson/8031 Mahindra/8032 Lonial/8020

Study phase 1b 1b 1 1 1/2

N 84 46 31 26 29

Dose-limiting toxicities

None observed (MTD not reached)

Neutropenia, febrile neutropenia,

thrombocytopenia, cardiac issues,

metabolic issues

Diarrhea Neutropenia, thrombocytopenia None observed

Selected ≥Grade 3 AEs

Neutropenia, thrombocytopenia,

anemia

Neutropenia, thrombocytopenia,

anemia

Neutropenia, thrombocytopenia, diarrhea, anemia,

fatigue

Neutropenia, thrombocytopenia

Febrile neutropenia, sepsis, enteritis,

diarrhea

ORR (≥PR)Prior lenalidomidePrior thalidomidePrior bortezomib

67%32/54 (59%)27/34 (79%)34/59 (58%)

41%0/4——

52%5/13 (38%)

——

11%———

82%

Adapted from Bensinger (abs 8029), Mateos (abs 8030), Richardson (abs 8031), Mahindra (abs 8032), Lonial (abs 8020).

6

New Combinations with Bortezomib in R/R MM Presented at ASCO 2010

PANOBINOSTAT ELOTUZUMAB VORINOSTAT

Author/Abstract No. San-Miguel/8001 Jakubowiak/8003 Jagannath/8133

Study phase(s) 1b 1 2b/3

N 47 28 83/172

Dose-limiting toxicities

Neutropenia, thrombocytopenia, pneumonia, fatigue, asthenia, dizziness, gastric hemorrhage

None observed Not reported

Selected ≥Grade 3 AEs

Thrombocytopenia, neutropenia, anemia, leukopenia, asthenia,

respiratory tract infection

Lymphopenia, fatigue, chest pain,

gastroenteritis

Thrombocytopenia, nausea, diarrhea

ORR (≥PR)

55%(all patients)

9/15 (60%)(bortezomib-refractory)

48%(all patients)

6/11 (55%)(prior bortezomib)

7/43 (16%)(bortezomib-refractory;

median 4.5 prior regimens)

Adapted from San-Miguel (abs 8001), Jakubowiak (abs 8003), Jagannath (abs 8133).

7

Romidepsin Shown to be Active in All 3 Disease Compartments in CTCL

ORR (PR + CR)n/N

CRn/N

Skin≥50% reduction in SWAT or erythroderma

40%(38/96)

8%(8/96)

Lymph node≥30% reduction in SLD

35%(13/37)

14%(5/37)

Blood≥50% reduction in Sézary cells

77%(10/13)

0

Skin + lymph node + bloodComposite endpoint

34%(33/96)

6%(6/96)

Adapted from Kim E, et al. ASCO 2010. Abstract 8047 (poster presentation).

SLD = sum of longest diameterSWAT = severity-weighted assessment tool

8

Denileukin Diftitox in CTCL

Placebo(n = 44)

Total DD(n = 263)

DD-naïve9 μg/kg(n = 80)

DD-naïve18 μg/kg(n = 118)

DD-treated18 μg/kg(n = 29)

DD-naïve18 μg/kg(n = 36)

Baseline stage ≤IIa 30 154 43 69 21 21

Baseline stage ≥IIb 14 109 37 49 8 15

ORR, % 16 38 31 47 28 31

Median duration of response, days 81 277 277 267 274 340

P value duration of response vs. placebo

— < 0.0001 0.0297 < 0.0001 0.0082 0.0036

CD25+ CD25–

Adapted from Duvic M, et al. ASCO 2010. Abstract 8055 (poster presentation).

9

CALGB 100104: TTP and OS

TIME TO PROGRESSION OVERALL SURVIVAL

Median Follow-up from randomization is 12 months

LenalidomideMedian TTP not reached

PlaceboMedian TTP 25.5 months

1.0

0.8

0.6

0.4

0.2

0.0

1.0

0.8

0.6

0.4

0.2

0.0

Prob

abili

ty

0 200 400 600 800 1000 1200 1400

Time since ASCT (days)0 200 400 600 800 1000 1200 1400

Time since ASCT (days)

Not long enough follow-up to determine difference in OS

Lenalidomide

Placebo

Lenalidomide arm: 11 deaths Placebo arm: 17 deaths

(P < 0.2)

Adapted from McCarthy PL, et al. ASCO 2010. Abstract 8017 (oral presentation).

10Lenalidomide Consolidation and Maintenance following First-line ASCT (3-year PFS)

0.00

0.25

0.50

0.75

1.00

0 6 12 18 24 30 36

HR 0.46P < 10–7

Lenalidomide3-year PFS: 68%

Placebo3-year PFS: 34%

Months

Prob

abili

ty

Adapted from Attal M, et al. ASCO 2010. Abstract 8018 (oral presentation).